Based on reported findings of the dysregulated metabolism in ALS patients and in vivo models of ALS, we tested the hypothesis that blocking or downregulation of lipid metabolism through CPT1 modulation affected disease progression in the SOD1 G93A mouse model of ALS. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.